Drugs & Targets FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) March 21, 2025Vol.51 No.11
Drugs & Targets EC expands approval for Breyanzi for r/r follicular lymphoma March 21, 2025Vol.51 No.11
Drugs & Targets EC approves Opdivo + Yervoy as first-line treatment for HCC March 14, 2025Vol.51 No.10
Drugs & Targets China’s National Medical Products Administration grants Breakthrough Therapy designation to olverembatinib for Ph+ ALL March 14, 2025Vol.51 No.10
Drugs & Targets FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer March 14, 2025Vol.51 No.10
Drugs & Targets University of New England licenses cancer biomarker test to Satya Diagnostics March 07, 2025Vol.51 No.09
Drugs & Targets FDA accepts review for odronextamab BLA in r/r follicular lymphoma February 28, 2025Vol.51 No.08
